Clinical Trial Update: An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab/Hyaluronidase in Slow-Growing Lymphomas That Have Come Back After Treatment or Have Not Responded to Treatment [Phase 1]

View source ↗

Summary

Early-phase trial evaluating a three-drug combination (venetoclax, lenalidomide, and rituximab with hyaluronidase) in relapsed or refractory B-cell non-Hodgkin …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma
• Follicular Lymphoma
• Indolent Non-hodgkin Lymphoma
• Marginal Zone Lymphoma

Drugs mentioned

• Revlimid (lenalidomide)
• Rituxan Hycela (rituximab/hyaluronidase)
• Venclyxto (Venetoclax)

Snippet

Sponsor: Thomas Jefferson University | Conditions: Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Follicular Lymphoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING